SIGLEC15 and invasive breast carcinoma: High Siglec15 levels are associated with poor prognosis in lung adenocarcinoma (LUAD) and kidney cancer, but are associated with better prognoses in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), head and neck squamous cell carcinoma (HNSC), thyroid cancer (THCA) and uterine corpus endometrial carcinoma (UCEC) 19-23.